PMP22 and Charcot-Marie-Tooth disease type 1A: Unfortunately, we failed to detect any significant variants within the PMP22 regulatory sequence that could be responsible for the gene-dosage effect and the observed clinical variability in the CMT1A/HNPP diseases [20].